Reimbursed Care Access in Zambia

Currently classified as a strictly controlled substance under Zambia’s narcotics/controlled-substances framework, with no authorized medical use outside of approved clinical research. Key national legislation that modernised Zambia’s controls includes the Narcotic Drugs and Psychotropic Substances Act (2021) and the Controlled Substances Act (2023), which provide the Drug Enforcement Commission and the national medicines authority with powers to control, licence and restrict manufacture, supply and use of listed psychotropic substances # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Zambia’s updated narcotics and controlled-substance statutes (see Narcotic Drugs and Psychotropic Substances Act 2021 and the Controlled Substances Act 2023) place MDMA and related entactogens within the scope of prohibited psychotropic substances administered by the Drug Enforcement Commission. Approved therapeutic use (for example, MDMA‑assisted psychotherapy) is not authorised or reimbursed in Zambia outside of licensed research. # #.

Esketamine (pharmaceutical Spravato or equivalent nasal esketamine products) is not listed on Zambia’s national essential medicines lists and there is no public record of registration or routine reimbursement of esketamine by Zambia’s medicines authority or public health procurement systems. Ketamine (racemate) is explicitly listed in Zambia’s essential medicines/anaesthesia sections and is widely used clinically as an anaesthetic; by contrast, esketamine requires country-level regulatory registration via the Zambia Medicines Regulatory Authority (ZAMRA) and there is no indication of such registration or public reimbursement for esketamine products in Zambia as of current national publications. Therefore esketamine is not available as a reimbursed treatment and would only be accessible if individually imported/registered under special import/licensing arrangements, subject to ZAMRA and controlled‑substance licensing. # #.

Ketamine (racemic injectable ketamine) is an authorised and listed medicine for anaesthesia in Zambia’s national essential medicines lists and is used in both public and private health facilities for surgical and emergency care; it is procured for public facilities under national essential-medicines procurement processes, although stock-outs and regional supply variability have been reported. Evidence: the Zambia Essential Medicines List includes ketamine (solution for injection) under anaesthetics, confirming its authorised medical use and routine inclusion in public-sector procurement lists. # #.

Regulatory and reimbursement context: Ketamine’s clinical use in Zambia is governed by national medicines regulation and by licensing/authorization provisions in the Controlled Substances Act (2023) and the prior Narcotic Drugs and Psychotropic Substances Act (2021); routine hospital use (including procurement and dispensing in government hospitals) is managed via Ministry of Health procurement guided by the national essential‑medicines list and public-sector budgets, not by an insurance reimbursement scheme. Public-sector provision of listed essential medicines (including ketamine) is normally funded via government procurement for hospitals and clinics, meaning patients receive ketamine for approved clinical indications (primarily anaesthesia/analgesia) within public services; however, availability can vary by facility and region, and ketamine formulations used for investigational psychiatric indications (e.g., repeated sub‑anaesthetic infusions for depression) are not part of standard public reimbursed protocols and would be considered off‑label clinical use in the Zambian context. For regulatory oversight and licensing of controlled medicines, ZAMRA and the Drug Enforcement Commission administer relevant controls under national law. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National statutes modernised in 2021 and 2023 list and empower authorities to prohibit psychotropic tryptamines such as DMT; therefore DMT possession, manufacture or supply for non‑research uses is illegal in Zambia. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT and related substituted tryptamines fall under the broad psychotropic/controlled substances framework administered by the Drug Enforcement Commission and regulated via ZAMRA licences for authorised research or medical use; there is no authorised clinical or reimbursed pathway for 5‑MeO‑DMT in Zambia. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised medical or reimbursed pathway for ibogaine in Zambia; any clinical or research use would require explicit licences under the national controlled‑substance regime. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While an ayahuasca brew is a botanical preparation rather than a single molecule, components such as DMT are controlled in Zambia; consequently ayahuasca and DMT‑containing brews have no authorised therapeutic or reimbursed status outside licensed research. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti preparations are therefore not authorised for medical reimbursement or general clinical use in Zambia. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The family of substituted phenethylamines (often referred to collectively as 2C‑series) is encompassed by Zambia’s psychotropic‑substance controls and may be specifically scheduled under national law; there is no authorised medical or reimbursed access in Zambia outside licenced research. # #.